Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- BLBD +9.2%, CNC +1.2% (guidance)
Other news:
- ICVX +47.1% (Icosavax to be acquires by AstraZeneca (AZN) for $15.00 pre share plus a non-tradable contingent value right to receive up to $5.00 in cash)
- GOTU +10.6% (report that the company's shopping channel subs increased on ByteDance)
- ADCT +9% (Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma)
- TARO +8.4% (agrees in principle to be acquired for $43.00/share)
- HARP +5.2% (Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of Recommended Phase 2 Dose)
- GERN +4.1% (Phase 3 presentation)
- IRON +3.6% (Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin and Other Programs at the 65th American Society of Hematology (ASH) Annual Meeting)
- WH +3.5% (Choice Hotels (CHH) launches exchange offer to acquire all outstanding shares of Wyndham Hotels & Resorts)
- SGEN +3.3% (Pfizer (PFE) receives all required regulatory approvals to complete the acquisition of Seagen; Expects to close Seagen acquisition on December 14 2023)
- HUT +2.9% (provides update on Hut 8's Stalking Horse Bid for four natural gas power plants including the North Bay Bitcoin mine)
- NOK +2.6% (provides an update on group strategy 2026 comparable operating margin target and preliminary assumptions for 2024)
- OLPX +2.4% (appoints new CEO)
- PRU +2% (authorizes $1.0 bln repurchase program)
- ADMA +1.9% (receives FDA approval for BIVIGAM in the pediatric patient setting for those 2 years of age and older)
- AZN +1.8% (Icosavax to be acquires by AstraZeneca (AZN) for $15.00 pre share plus a non-tradable contingent value right to receive up to $5.00 in cash)
- GRCL +1.6% (Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023)
- SBLK +1.2% (combining with Eagle Bulk Shipping)
- SNY +1.1% (releases statement on FTC challenge)
- RGTI +1% (files $250 mln mixed shelf)
Analyst comments:
- HUBS +2.3% (upgraded to Overweight from Neutral at Piper Sandler)
- AMAL +1.6% (upgraded to Overweight from Neutral at JP Morgan)
- DGX +1.2% (upgraded to Buy from Neutral at BofA Securities)